{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:25:16Z","timestamp":1792409116191,"version":"4.4.0"},"reference-count":34,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,2,14]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy of slow release oral morphine (SROM) as a treatment for opioid use disorder (OUD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of randomised controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Three electronic databases were searched through 1 May 2018: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We also searched the following electronic registers for ongoing trials: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the EU Clinical Trials Register.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>We included RCTs of all durations, assessing the effect of SROM on measures of treatment retention, heroin use and craving in adults who met the diagnostic criteria for OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>\n                      Two independent reviewers extracted data and assessed risk of bias. Data were pooled using the random-effects model and expressed as risk ratios (RRs) or mean differences with 95% CIs. Heterogeneity was assessed (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      statistic) and quantified (I\n                      <jats:sup>2<\/jats:sup>\n                      statistic) and a sensitivity analysis was undertaken to assess the impact of particular high-risk trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1315 records screened and four studies reviewed, four unique randomised trials met the inclusion criteria (n=471), and compared SROM with methadone. In the meta-analysis, we observed no significant differences between SROM and methadone in improving treatment retention\n                      <jats:bold>(<\/jats:bold>\n                      RR=0.98; 95%CI: 0.94 to 1.02, p=0.34) and heroin use (RR=0.96; 95%\u2009CI: 0.61 to 1.52, p=0.86). Craving data was not amenable to meta-analysis. Available data implied no differences in adverse events, heroin, cocaine or benzodiazepine use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Meta-analysis of existing randomised trials suggests SROM may be generally equal to methadone in retaining patients in treatment and reducing heroin use while potentially resulting in less craving. The methodological quality of the included RCTs was low-to-moderate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025799","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:34:47Z","timestamp":1554276887000},"page":"e025799","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Slow release oral morphine versus methadone for the treatment of opioid use disorder"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-0052","authenticated-orcid":false,"given":"Jan","family":"Klimas","sequence":"first","affiliation":[{"name":"BC Centre on Substance Use, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gorfinkel","sequence":"additional","affiliation":[{"name":"Columbia University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore M","family":"Giacomuzzi","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik Innsbruck-Ambulanz f\u00fcr Abh\u00e4ngigkeitserkrankungen, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ruckes","sequence":"additional","affiliation":[{"name":"University Medical Center Mainz, Interdisciplinary Center Clinical Trials, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"2025121514563371000_9.4.e025799.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.11859"},{"key":"2025121514563371000_9.4.e025799.2","unstructured":"NIDA. WMOverdose Death Rates: National Institute on Drug Abuse, 2017."},{"key":"2025121514563371000_9.4.e025799.3","unstructured":"(WHO); WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: Switzerland, 2009."},{"key":"2025121514563371000_9.4.e025799.4","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2025121514563371000_9.4.e025799.5","unstructured":"(ASAM); ASoAM. The national practice guideline for the use of medications in the treatment of addiction involving opioid use, 2015."},{"key":"2025121514563371000_9.4.e025799.6","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121514563371000_9.4.e025799.7","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"66","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121514563371000_9.4.e025799.8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7326\/M17-2373","article-title":"Evaluating slow-release oral morphine to narrow the treatment gap for opioid use disorders","volume":"168","author":"Soc\u00edas","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025121514563371000_9.4.e025799.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1996.tb03800.x"},{"key":"2025121514563371000_9.4.e025799.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"2025121514563371000_9.4.e025799.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00171-5"},{"key":"2025121514563371000_9.4.e025799.12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/1353-1131(94)90008-6","article-title":"The promise, problems and limitations of methadone: a clinical perspective","volume":"1","author":"White","year":"1994","journal-title":"J Clin Forensic Med"},{"issue":"3-4","key":"2025121514563371000_9.4.e025799.13","first-page":"66","article-title":"Physical effects of methadone maintenance treatment from the standpoint of clients","volume":"2","author":"Kheradmand","year":"2010","journal-title":"Addict Health"},{"key":"2025121514563371000_9.4.e025799.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025121514563371000_9.4.e025799.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03923.x"},{"key":"2025121514563371000_9.4.e025799.16","first-page":"CD009879","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence","volume":"6","author":"Ferri","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121514563371000_9.4.e025799.17","doi-asserted-by":"publisher","DOI":"10.1111\/add.12440"},{"key":"2025121514563371000_9.4.e025799.18","first-page":"CD003410","article-title":"Heroin maintenance for chronic heroin-dependent individuals","volume":"12","author":"Ferri","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121514563371000_9.4.e025799.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025121514563371000_9.4.e025799.20","unstructured":"Clark NC . Expanding the Options for the Treatment of Heroin Dependence with Oral Supervised Opioid Substitution Therapy: LAAM, Buprenorphine and Slow Release Oral Morphine as Alternatives to Methadone: University of Melbourne, Department of Medicine, St Vincent\u2019s Hospital, 2006."},{"key":"2025121514563371000_9.4.e025799.21","unstructured":"Substance-Related and Addictive Disorders. American Psychiatry Association: American Psychiatric Publishing, 2013."},{"key":"2025121514563371000_9.4.e025799.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.036"},{"key":"2025121514563371000_9.4.e025799.23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JCP.0000000000000288","article-title":"Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial","volume":"35","author":"Falcato","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2025121514563371000_9.4.e025799.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.05.012"},{"key":"2025121514563371000_9.4.e025799.25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000113724","article-title":"Quality of life in patients receiving opioid maintenance therapy. A comparative study of slow-release morphine versus methadone treatment","volume":"14","author":"Winklbaur","year":"2008","journal-title":"Eur Addict Res"},{"key":"2025121514563371000_9.4.e025799.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.001128.x"},{"key":"2025121514563371000_9.4.e025799.27","doi-asserted-by":"publisher","DOI":"10.1080\/10826080500391845"},{"key":"2025121514563371000_9.4.e025799.28","article-title":"A randomised trial of once-daily slow-release oral morphine versus methadone for heroin dependence","volume":"Suppl 1","author":"Clark","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"key":"2025121514563371000_9.4.e025799.29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000368572","article-title":"Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study","volume":"21","author":"Verthein","year":"2015","journal-title":"Eur Addict Res"},{"key":"2025121514563371000_9.4.e025799.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1706626"},{"key":"2025121514563371000_9.4.e025799.31","first-page":"CD011669","article-title":"Morphine for chronic neuropathic pain in adults","volume":"352","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121514563371000_9.4.e025799.32","unstructured":"EMCDDA. Year of introduction of methadone maintenance treatment, high-dosage buprenorphine treatment, heroin-assisted treatment, slow-realease morphine and suboxone lisbon: European monitoring centre for drugs and drug addiction. 2009 http:\/\/www.emcdda.europa.eu\/stats09\/hsrtab1 (Accessed 13 Apr 2018)."},{"key":"2025121514563371000_9.4.e025799.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7529.1352"},{"key":"2025121514563371000_9.4.e025799.34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:56:39Z","timestamp":1765839399000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,2]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bmjopen-2018-025799"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025799","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}